Clinical Trials
Novartis discontinues ASA404 clinical trial program and shifts focus...
Novartis announced that the clinical trial program for the investigational cancer treatment ASA404 (vadimezan) will be discontinued and resources will be reallocated to other compounds...
Clinical Trials
Genentech announced the result of Phase II clinical trail...
Genentech, Inc., a member of the Roche Group announced results from a Phase II clinical study of RG7204 (PLX4032), an investigational first-in-class molecule designed to...
Clinical Trials
Sanofi Pasteur’s Dengue Vaccine in Final Stage of Clinical...
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur’s dengue vaccine, the...
Clinical Trials
Roche reports promising Phase II results with new targeted...
Roche announced results from a Phase II clinical study of RG7204 PLX4032), an investigational first-in-class molecule designed to selectively inhibit a cancer-causing, mutated form of...
Clinical Trials
Genzyme Announces Results of Phase 3 Trial of Clolar...
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine...
Clinical Trials
Boehringer Ingelheim announced approval for TWYNSTA®. TWYNSTA single pill...
Boehringer Ingelheim announced today that the European Commission confirmed the positive opinion of the European Medicines Agency (EMA) approving TWYNSTA®. TWYNSTA® is indicated for the...
Clinical Trials
Amgen announced that results from the PRIME ‘203’ and...
Amgen announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix(R) (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.